{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T04:47:28Z","timestamp":1776314848025,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Research Foundation of Korea [NRF] grants funded by the Korean government [MSIT]","award":["NRF-2023R1A2C2006375"],"award-info":[{"award-number":["NRF-2023R1A2C2006375"]}]},{"name":"Future Medicine 2030 Project of the Samsung Medical Center","award":["#SMO1250061"],"award-info":[{"award-number":["#SMO1250061"]}]},{"name":"Future Medicine 2030 Project of the Samsung Medical Center","award":["#SMX1250111"],"award-info":[{"award-number":["#SMX1250111"]}]},{"name":"National Research Foundation of Korea (NRF) grants funded by the Korean government","award":["NRF-2023R1A2C2004339"],"award-info":[{"award-number":["NRF-2023R1A2C2004339"]}]},{"name":"Bio&Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government","award":["No. RS-2023-00225255"],"award-info":[{"award-number":["No. RS-2023-00225255"]}]},{"name":"National Research Foundation of Korea (NRF) grant funded by the Korea government","award":["RS-2025-00519956"],"award-info":[{"award-number":["RS-2025-00519956"]}]},{"name":"Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea","award":["RS-2020-KH088685"],"award-info":[{"award-number":["RS-2020-KH088685"]}]},{"name":"grant of Korean ARPA-H Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea","award":["RS-2024-00512539"],"award-info":[{"award-number":["RS-2024-00512539"]}]},{"name":"grant of the Korea-US Collaborative Research Fund(KUCRF), funded by the Ministry of Science and ICT and Ministry of Health & Welfare, Republic of Korea","award":["RS-2024-00466776"],"award-info":[{"award-number":["RS-2024-00466776"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04245-3","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T12:15:08Z","timestamp":1766060108000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Elevated antidrug antibodies against atezolizumab and associated clinical outcomes in advanced non-small-cell lung cancer"],"prefix":"10.1007","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5046-161X","authenticated-orcid":false,"given":"Miran","family":"Jang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9780-6155","authenticated-orcid":false,"given":"Chan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8988-8258","authenticated-orcid":false,"given":"So Jung","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2252-7041","authenticated-orcid":false,"given":"Hannah","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2753-5294","authenticated-orcid":false,"given":"Won Suk","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9960-5648","authenticated-orcid":false,"given":"Ho Yun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6979-5812","authenticated-orcid":false,"given":"Hong Jae","family":"Chon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9219-3350","authenticated-orcid":false,"given":"Se-Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"issue":"10","key":"4245_CR1","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/s41571-023-00794-7","volume":"20","author":"G Mountzios","year":"2023","unstructured":"Mountzios G, Remon J, Hendriks LEL et al (2023) Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challenges. Nat Rev Clin Oncol 20(10):664\u2013677. https:\/\/doi.org\/10.1038\/s41571-023-00794-7","journal-title":"Nat Rev Clin Oncol"},{"key":"4245_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.955440","volume":"12","author":"F Yang","year":"2022","unstructured":"Yang F, Wang Y, Tang L et al (2022) Efficacy of immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis. Front Oncol 12:955440. https:\/\/doi.org\/10.3389\/fonc.2022.955440","journal-title":"Front Oncol"},{"issue":"8","key":"4245_CR3","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/j.jtho.2018.04.039","volume":"13","author":"L Fehrenbacher","year":"2018","unstructured":"Fehrenbacher L, von Pawel J, Park K et al (2018) Updated efficacy analysis including secondary population results for OAK: a randomized phase III study of atezolizumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer. J Thorac Oncol 13(8):1156\u20131170. https:\/\/doi.org\/10.1016\/j.jtho.2018.04.039","journal-title":"J Thorac Oncol"},{"issue":"10030","key":"4245_CR4","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","volume":"387","author":"L Fehrenbacher","year":"2016","unstructured":"Fehrenbacher L, Spira A, Ballinger M et al (2016) Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387(10030):1837\u20131846. https:\/\/doi.org\/10.1016\/S0140-6736(16)00587-0","journal-title":"Lancet"},{"issue":"24","key":"4245_CR5","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski MA, Jotte RM, Cappuzzo F et al (2018) Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 378(24):2288\u20132301. https:\/\/doi.org\/10.1056\/NEJMoa1716948","journal-title":"N Engl J Med"},{"issue":"10066","key":"4245_CR6","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer A, Barlesi F, Waterkamp D et al (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389(10066):255\u2013265. https:\/\/doi.org\/10.1016\/S0140-6736(16)32517-X","journal-title":"Lancet"},{"issue":"1","key":"4245_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0586-0","volume":"7","author":"J Davda","year":"2019","unstructured":"Davda J, Declerck P, Hu-Lieskovan S, Hickling TP, Jacobs IA, Chou J, Salek-Ardakani S, Kraynov E (2019) Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics. J Immunother Cancer 7(1):105. https:\/\/doi.org\/10.1186\/s40425-019-0586-0","journal-title":"J Immunother Cancer"},{"key":"4245_CR8","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.3389\/fimmu.2020.01951","volume":"11","author":"A Vaisman-Mentesh","year":"2020","unstructured":"Vaisman-Mentesh A, Gutierrez-Gonzalez M, DeKosky BJ, Wine Y (2020) The molecular mechanisms that underlie the immune biology of anti-drug antibody formation following treatment with monoclonal antibodies. Front Immunol 11:1951. https:\/\/doi.org\/10.3389\/fimmu.2020.01951","journal-title":"Front Immunol"},{"issue":"1","key":"4245_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0791-x","volume":"7","author":"CS Shemesh","year":"2019","unstructured":"Shemesh CS, Chanu P, Jamsen K et al (2019) Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer. J Immunother Cancer 7(1):314. https:\/\/doi.org\/10.1186\/s40425-019-0791-x","journal-title":"J Immunother Cancer"},{"issue":"2","key":"4245_CR10","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/cpt.587","volume":"102","author":"M Stroh","year":"2017","unstructured":"Stroh M, Winter H, Marchand M et al (2017) Clinical pharmacokinetics and pharmacodynamics of atezolizumab in metastatic urothelial carcinoma. Clin Pharmacol Ther 102(2):305\u2013312. https:\/\/doi.org\/10.1002\/cpt.587","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"4245_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008266","volume":"12","author":"P Galle","year":"2024","unstructured":"Galle P, Finn RS, Mitchell CR, Ndirangu K, Ramji Z, Redhead GS, Pinato DJ (2024) Treatment-emergent antidrug antibodies related to PD-1, PD-L1, or CTLA-4 inhibitors across tumor types: a systematic review. J Immunother Cancer 12(1):e008266. https:\/\/doi.org\/10.1136\/jitc-2023-008266","journal-title":"J Immunother Cancer"},{"issue":"12","key":"4245_CR12","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1001\/jamaoncol.2022.4733","volume":"8","author":"C Kim","year":"2022","unstructured":"Kim C, Yang H, Kim I et al (2022) Association of high levels of antidrug antibodies against atezolizumab with clinical outcomes and T-cell responses in patients with hepatocellular carcinoma. JAMA Oncol 8(12):1825\u20131829. https:\/\/doi.org\/10.1001\/jamaoncol.2022.4733","journal-title":"JAMA Oncol"},{"issue":"4","key":"4245_CR13","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1158\/1078-0432.CCR-19-2337","volume":"26","author":"D Enrico","year":"2020","unstructured":"Enrico D, Paci A, Chaput N, Karamouza E, Besse B (2020) Antidrug antibodies against immune checkpoint blockers: impairment of drug efficacy or indication of immune activation? Clin Cancer Res 26(4):787\u2013792. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2337","journal-title":"Clin Cancer Res"},{"issue":"11","key":"4245_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11111689","volume":"11","author":"EG Giannini","year":"2019","unstructured":"Giannini EG, Aglitti A, Borzio M et al (2019) Overview of immune checkpoint inhibitors therapy for hepatocellular carcinoma, and the ITA.LI.CA cohort derived estimate of amenability rate to immune checkpoint inhibitors in clinical practice. Cancers (Basel) 11(11):1689. https:\/\/doi.org\/10.3390\/cancers11111689","journal-title":"Cancers (Basel)"},{"key":"4245_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.681320","volume":"12","author":"JB Lee","year":"2021","unstructured":"Lee JB, Ha SJ, Kim HR (2021) Clinical insights into novel immune checkpoint inhibitors. Front Pharmacol 12:681320. https:\/\/doi.org\/10.3389\/fphar.2021.681320","journal-title":"Front Pharmacol"},{"issue":"1","key":"4245_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13045-021-01056-8","volume":"14","author":"JA Marin-Acevedo","year":"2021","unstructured":"Marin-Acevedo JA, Kimbrough EO, Lou Y (2021) Next generation of immune checkpoint inhibitors and beyond. J Hematol Oncol 14(1):45. https:\/\/doi.org\/10.1186\/s13045-021-01056-8","journal-title":"J Hematol Oncol"},{"issue":"8","key":"4245_CR17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.26252","volume":"5","author":"L Pala","year":"2022","unstructured":"Pala L, Sala I, Oriecuia C et al (2022) Association of anticancer immune checkpoint inhibitors with patient-reported outcomes assessed in randomized clinical trials: a systematic review and meta-analysis. JAMA Netw Open 5(8):e2226252. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.26252","journal-title":"JAMA Netw Open"},{"issue":"8","key":"4245_CR18","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","volume":"28","author":"AX Zhu","year":"2022","unstructured":"Zhu AX, Abbas AR, de Galarreta MR et al (2022) Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med 28(8):1599\u20131611. https:\/\/doi.org\/10.1038\/s41591-022-01868-2","journal-title":"Nat Med"},{"issue":"5","key":"4245_CR19","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1424674","volume":"7","author":"AH Kverneland","year":"2018","unstructured":"Kverneland AH, Enevold C, Donia M, Bastholt L, Svane IM, Nielsen CH (2018) Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab. Oncoimmunology 7(5):e1424674. https:\/\/doi.org\/10.1080\/2162402X.2018.1424674","journal-title":"Oncoimmunology"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04245-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04245-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04245-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T12:15:09Z","timestamp":1766060109000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04245-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["4245"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04245-3","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"9 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hong Jae Chon holds consulting or advisory roles with Eisai, Roche, Bayer, ONO, MSD, BMS, BeOne, Boehringer Ingelheim, Sanofi, Servier, AstraZeneca, and IMBDx, and has received research grants from Roche, BeOne, Guardant Health, Servier, HANDOK Inc., Dong-A ST, and Boryung Pharmaceuticals.\u00a0The\u00a0other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study received approval from the institutional review board of Samsung Medical Center and adhered to the principles of the Helsinki Declaration.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"8"}}